摘要
生产厂家以金葡菌肠毒素C2(SEC2)的标示量作为金葡素注射液的质量控制标准,但其真正的含量由于滤液成分复杂而很难检测,本实验试图建立一种方便的鉴定金葡素注射液中的SEC2的方法。首先将重组的SEC2分别免疫BALB/c小鼠和新西兰兔,制备并纯化了单克隆及多克隆抗体。采用自制的抗体建立了检测SEC2的生物素-链霉亲和素酶联免疫吸附实验,检测目标蛋白的质量浓度范围为2～20ng.mL-1,在检测范围内检测值的平均变异系数为5.08%,采用本法检测质量浓度分别为100ng.mL-1的重组肠毒素(SEA/SEO/SEM/SEN/SEG/SEI),均呈现阴性反应,说明此检测方法的专一性较好。采用此方法对金葡素注射液中的SEC2含量进行了检测,发现SEC2标识量与实际含量存在一定的差距。
The filtrate of Staphylococcus aureus culture has been used in an ampule form named as staphylococcal enterotoxin C injection for cancer therapy in clinic for ten years in China and proved to be effective. The active constituent of three kinds of injections is claimed to be staphylococcal enterotoxin C2 （ SEC2 ） , and the content of SEC2 is used as quality control. However, the correct content of SEC2 was not known and the relative amount of SEC2 was very low because of the complicated components of the filtrate. In this research, we established a proper ELISA system for the detection of SEC2 in staphylococcal enterotoxin C injection, which will improve the quality control of the injection. We produced and identified polyclonal and monoclonal antibodies of SEC2 and established BA-ELISA method based on the method of sandwich ELISA. It was found that the BA-ELISA method had good specificity, sensitivity and reproducibility, and being able to detect SEC2 at concentration from 2 to 20 ng · mL^-1, with an average CV value of 5.08%. The SEC2 content in staphylococcal enterotoxin C injection was calculated. There is some difference between the actual and labeled contents in the injections.
出处
《药学学报》
CAS
CSCD
北大核心
2008年第8期801-805,共5页
Acta Pharmaceutica Sinica
基金
浙江省科技厅资助项目(2004C13041)
